0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

The Effect of Antilymphocyte Induction Therapy on Renal Allograft Survival: A Meta-Analysis of Individual Patient-Level Data

Lynda Anne Szczech, MD, MS; Jesse A. Berlin, ScD; and Harold I. Feldman, MD, MS
[+] Article and Author Information

For the Anti-Lymphocyte Antibody Induction Therapy Study Group* *For members of the Anti-Lymphocyte Antibody Induction Therapy Study Group, see Appendix. From the University of Pennsylvania, Philadelphia, Pennsylvania; and New York Medical College, Valhalla, New York. Grant Support: In part by National Institutes of Health Training Grant DK-07006, National Institutes of Health Center Grant DK-45191, and administrative and educational funds from the DCI Research and Education Development Fund. Dr. Szczech was supported in part as a Clinician Scientist in Nephrology by the American Kidney Fund. Dr. Feldman is an Established Investigator of the American Heart Association. Requests for Reprints: Harold I. Feldman, MD, MS, University of Pennsylvania Medical Center, Center for Clinical Epidemiology and Biostatistics, 720 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104-6021. Current Author Addresses: Dr. Szczech: Westchester Medical Center, Division of Nephrology, New York Medical College, Valhalla, NY 10595.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1998;128(10):817-826. doi:10.7326/0003-4819-128-10-199805150-00004
Text Size: A A A

Purpose: Randomized, controlled trials have not shown that the perioperative use of antilymphocyte antibodies (induction therapy) improves survival of cadaveric kidney allografts. This study combined individual patient-level data from published trials to examine the effect of induction therapy on allograft survival.

Data Sources: Randomized, controlled trials identified from MEDLINE.

Study Selection: Published trials that compared adult recipients of cadaveric renal allografts who did and did not receive antilymphocyte antibodies in the perioperative period were selected if individual patient-level data were available.

Data Extraction and Analysis: Individual patient-level data were collected for each of 628 study patients. Multi-variable Cox proportional-hazards regression was used to estimate the effect of induction therapy on allograft survival.

Results: The adjusted rate ratio for allograft failure with induction therapy compared with conventional therapy was 0.62 (95% CI, 0.43 to 0.90) (P = 0.012) over 2 years and 0.82 (CI, 0.62 to 1.09) (P = 0.17) over 5 years. The effect of induction therapy on allograft survival diminished over time; no benefit overall was seen after 2 years after transplantation (rate ratio, 1.13 [CI, 0.72 to 1.78]) (P > 0.02). Greater HLA-DR mismatch, delayed allograft function, diabetes mellitus in the recipient, African-American ethnicity of the recipient, and presensitization (panel-reactive antibody levels ≥ 20%) were significantly associated with allograft failure at 5 years. Among high-risk patients, only those who were presensitized benefited from induction therapy at 2 years (rate ratio, 0.12 [CI, 0.03 to 0.44]) (P = 0.001). Results were similar at 5 years.

Conclusions: Using individual-level data, this study showed a benefit of induction therapy at 2 years, particularly among presensitized patients. Although the benefit of this therapy subsequently waned, presensitized patients continued to have benefit at 5 years.

Figures

Grahic Jump Location
Figure 1.
Overall unadjusted Kaplan-Meier survival curves.

The proportion of patients with surviving allografts is plotted against survival time in days over 5 years, stratified by treatment. IT = induction therapy.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Kaplan-Meier survival curves of allograft survival according to immunosuppressive regimen and presensitization (panel-reactive antibody [PRA] levels <20% or ≥ 20%). Top.Bottom.

At 2 years. At 5 years.

Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)